Coronary StenosisVIPNCT03606330
Systemic, Pancoronary and Local Coronary Vulnerability
An observational study of Coronary Stenosis and Acute Coronary Syndrome, run by Cardio Med Medical Center at 1 site in Romania.
Trial summary
The aim of the VIP study is to investigate the impact of vulnerability markers (inflammatory serum biomarkers for systemic vulnerability, coronary shear stress and vulnerability mapping for pancoronary vulnerability, and imaging-based plaque features for systemic vulnerability) on the rate of major adverse… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction
- What is being tested?
- Cardiac imaging tests and Venous blood sample collection
- How many people
- 100 participants
- Where
- 1 siteRomania
- Study dates
- 22 Oct 2018to 1 Mar 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 100 patients with present ST and non-ST segment elevation myocardial infarction at 30 days prior to study enrollment, who underwent emergency revascularization of the culprit lesion.
Who may be able to join
- Patients aged over 18 years old that have signed the written informed consent;
- Patients with ST and non-ST segment elevation myocardial infarction (as stated in the Third Universal Definition of Myocardial Infarction) at 30 days prior to randomization;
Who cannot join
- unwillingness or incapacity to provide informed consent (and if consent of legal guardian or family is not available);
- acute myocardial infarction at the moment of randomization (as these patients are referred to the hospital for emergency invasive coronary angiography and revascularization)
- conditions that present an estimated life expectancy of under 5 years;
- acute renal failure or terminal stage chronic kidney disease;
- pregnancy or lactation and women of reproductive age who are not using any contraceptive method;
- allergy and history of allergic reactions to iodine contrast media;
- active malignancy or malignancy within the last 1 year prior to enrollment;
- patients who, in the opinion of the investigators are not compliant and will not present for study visits.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Systemic, Pancoronary and Local Plaque Vulnerability for Image-based Prediction of Acute Coronary Syndromes - the VIP Study
- The aim of the VIP study is to investigate the impact of vulnerability markers (inflammatory serum biomarkers for systemic vulnerability, coronary shear stress and vulnerability mapping for pancoronary vulnerability, and imaging-based plaque features for systemic vulnerability) on the rate of major adverse cardiovascular events caused by progression of the non-culprit lesion in patients with acute ST or non-ST segment elevation myocardial infarction who undergo revascularization of the culprit lesion during the acute event. Furthermore, the study will evaluate the rate of progression of non-culprit lesions towards a higher degree of vulnerability, based on coronary computed tomography angiographic assessment at 1 year after enrollment.
Read the detailed description
The project is a prospective, cohort, mono-centric study which will be carried out in the Center of Advanced Research in Multimodal Cardiac Imaging Cardiomed.
The project will include 100 subjects who present ST and non-ST segment elevation myocardial infarction at 30 days prior to study enrollment, who underwent emergency revascularization of the culprit lesion. Samples for systemic serum biomarkers for myocardial injury, myocardial strain and enhanced systemic inflammation will be collected at the moment of the acute event. All patients will undergo coronary CT angiography, cardiac perfusion CT and intracoronary imaging procedures (Intravascular ultrasound - IVUS; Optical Coherence Tomography - OCT) at the moment of enrollment in the study, for complex assessment of non-culprit coronary lesions. The endothelial coronary shear stress will be calculated with imaging post-processing techniques on the CT data acquired at baseline, by using computational fluid dynamics.
The study will be conducted over a period of 3 years, in which patients will be examined at baseline, and during several follow-up visits. At the one-year follow-up, the study subjects will undergo CT coronary angiography for re-evaluation of the non-culprit lesions, in the prospects of analyzing the rate of plaque progression towards a higher degree of vulnerability. At the end of the 3-year period, patients will be assessed about the occurrence of major adverse cardiovascular events and the rate or revascularization for non-culprit lesions.
Study objectives:
Primary: to investigate the association between systemic, pancoronary and local vulnerability features of coronary plaques and the risk for major adverse cardiac events - MACE (all-cause mortality, cardiovascular death, myocardial infarction, repeated revascularization, repeated hospitalizations for cardiovascular related incidents, cerebrovascular events) during a 3-year follow-up.
Secondary: to assess the rate of progression for the non-culprit lesions towards a higher degree of vulnerability, as evaluated via coronary CT angiography at 1 year after enrollment, in relation to systemic, pancoronary and local vulnerability features at baseline.
To identify the type of vulnerability (systemic, pancoronary or local) with the highest impact on plaque progression and future MACE
Study Timeline:
Baseline (day 0)
- Obtain and document consent from participant on study consent form.
- Verify inclusion/exclusion criteria.
- Obtain demographic information, medical history, medication history, alcohol and tobacco use history.
- Record results of physical examinations and 12-lead ECG.
- Collect blood specimens.
- Imaging procedures: transthoracic 2-D echocardiography, 128-multisclice CT angiography, cardiac perfusion CT, IVUS, OCT
Visit 1 (month 1)
- Record results of physical examinations, 12-lead ECG and medical history.
- Imaging procedures: transthoracic 2-D echocardiography
Visit 2 (month 3)
- Telephone follow-up
Visit 3 (month 6)
- Record results of physical examinations, 12-lead ECG and medical history.
- Imaging procedures: transthoracic 2-D echocardiography
Visit 4 (month 12)
- Record results of physical examinations, 12-lead ECG and medical history.
- Imaging procedures: transthoracic 2-D echocardiography, 128-multislice CT coronary angiography for evaluation of non-culprit lesion
- End-point evaluation
Visit 5 (month 15)
- Telephone follow-up
Visit 6 (month 18)
- Telephone follow-up
Visit 7 (month 24)
- Record results of physical examinations, 12-lead ECG and medical history.
- Imaging procedures: transthoracic 2-D echocardiography.
- End-point evaluation
Visit 8 (month 30)
- Telephone follow-up
Final study visit (month 36)
- Record results of physical examinations, 12-lead ECG and medical history.
- Imaging procedures: transthoracic 2-D echocardiography
- End-point evaluation.
Study procedures:
- Clinical examination, medical history
- 12-lead ECG
- 2D transthoracic echocardiography with measurement of: cardiac diameters, volumes, valvular function and regurgitation, pressure gradients, pericardial fat thickness, pericardial effusion, left ventricular global and regional function and ejection fraction.
- 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity (degree of stenosis, lesion length, lumen area and diameter, minimum and maximum plaque thickness); morphological plaque characteristics (plaque related volumes, plaque burden, vascular indexes - remodeling and eccentricity index); plaque components evaluated via volumetric and planimetric units (necrotic core, fibrofatty tissue, fibrotic tissue, dense calcium); markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).
- Shear stress evaluation of CT acquired images and computational fluid dynamics
- Intracoronary imaging techniques: IVUS and OCT with evaluation of plaque characteristics.
- Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
Data collection: In a dedicated database that includes all patient information, demographics, medical history, medication, therapeutic procedures, information derived from imaging techniques (echocardiography, CT angiography, CT imaging post-processing and shear stress evaluation).
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques, Atheroscleroses, Coronary, Non-ST Elevation Myocardial Infarction (nSTEMI)
- Being tested
- Cardiac imaging tests, Venous blood sample collection
- Keywords
- coronary artery disease, myocardial infarction, cardiac imaging techniques, major adverse cardiovascular events, vulnerable coronary plaques, serum biomarkers, coronary shear stress
- Medical subject headings
- Coronary Stenosis, Acute Coronary Syndrome, Plaque, Atherosclerotic, Coronary Artery Disease, Non-ST Elevated Myocardial Infarction, Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cardiac imaging testsDiagnostic test
- 2D transthoracic echocardiography
- 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).
- Shear stress evaluation via computational fluid dynamics.
- Intracoronary imaging techniques: IVUS and OCT.
Venous blood sample collectionDiagnostic test
Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
| Study group | Role | What they receive |
|---|---|---|
| VP-SG 01 | Study subjects that present MACE at the 36 months follow-up Receives: Diagnostic Test: Cardiac imaging tests; Diagnostic Test: Venous blood sample collection | |
| VP-SG 02 | Study subjects that do not present MACE at the 36 months follow-up Receives: Diagnostic Test: Cardiac imaging tests; Diagnostic Test: Venous blood sample collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
MACE rate - Major adverse cardiovascular events
Acute coronary syndromes (unstable angina, ST and non-ST elevation myocardial infarction), emergency revascularization of non-culprit lesions, repeated hospitalizations for cardiovascular reasons, acute cerebrovascular event.
Measured: 36 months
Secondary outcomes (2)
Severity progression of non-culprit coronary lesions
Reevaluation of the non-culprit lesions via 128-multislice CT coronary angiography with analysis of the degree of stenosis caused by the non-culprit lesion.
Measured: 12 months
Progression rate of CT markers for coronary plaque vulnerability
Reevaluation of the non-culprit lesions via 128-multislice CT coronary angiography with analysis of the number of CT markers for coronary plaque vulnerability (low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2018
- Study start22 Oct 2018
- Primary completion22 Oct 2019
- Study completion1 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary StenosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cardio Med Medical Center
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- University of Targu Mures, Romania, University Hospital of Targu Mures, Romania
- Responsible party
- Sponsor
- Investigators
- Theodora Benedek, Professor, Study director, Cardio Med Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03606330
- Sponsor's protocol ID
- CM0118-PLI-3
- Acronym
- VIP
- Status last verified
- Dec 2019
- First submitted
- 26 Jun 2018
- Last updated
- 2 Aug 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD that underlie results in a publication will be available for interested parties.
Study at a glance
From the registry record, last updated by the sponsor on 2 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Systemic, Pancoronary and Local Plaque Vulnerability for Image-based Prediction of Acute Coronary Syndromes - the VIP Study
- ClinicalTrials.gov ID
- NCT03606330
- Acronym / sponsor ID
- VIP / CM0118-PLI-3
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques, Atheroscleroses, Coronary, Non-ST Elevation Myocardial Infarction (nSTEMI)
- Keywords
- coronary artery disease, myocardial infarction, cardiac imaging techniques, major adverse cardiovascular events, vulnerable coronary plaques, serum biomarkers, coronary shear stress
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Cardio Med Medical CenterIndustry (pharma, biotech, devices)
- Collaborators
- University of Targu Mures, Romania, University Hospital of Targu Mures, Romania
- Study start
- 22 Oct 2018 (actual)
- Primary completion
- 22 Oct 2019 (actual)
- Study completion
- 1 Mar 2022 (actual)
- First posted
- 30 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- The aim of the VIP study is to investigate the impact of vulnerability markers (inflammatory serum biomarkers for systemic vulnerability, coronary shear stress and vulnerability mapping for pancoronary vulnerability, and imaging-based plaque features for systemic vulnerability) on the rate of major adverse cardiovascular events caused by progression of the non-culprit lesion in patients with acute ST or non-ST segment elevation myocardial infarction who undergo revascularization of the culprit lesion during the acute event. Furthermore, the study will evaluate the rate of progression of non-culprit lesions towards a higher degree of vulnerability, based on coronary computed tomography angiographic assessment at 1 year after enrollment.
Detailed description
The project is a prospective, cohort, mono-centric study which will be carried out in the Center of Advanced Research in Multimodal Cardiac Imaging Cardiomed.
The project will include 100 subjects who present ST and non-ST segment elevation myocardial infarction at 30 days prior to study enrollment, who underwent emergency revascularization of the culprit lesion. Samples for systemic serum biomarkers for myocardial injury, myocardial strain and enhanced systemic inflammation will be collected at the moment of the acute event. All patients will undergo coronary CT angiography, cardiac perfusion CT and intracoronary imaging procedures (Intravascular ultrasound - IVUS; Optical Coherence Tomography - OCT) at the moment of enrollment in the study, for complex assessment of non-culprit coronary lesions. The endothelial coronary shear stress will be calculated with imaging post-processing techniques on the CT data acquired at baseline, by using computational fluid dynamics.
The study will be conducted over a period of 3 years, in which patients will be examined at baseline, and during several follow-up visits. At the one-year follow-up, the study subjects will undergo CT coronary angiography for re-evaluation of the non-culprit lesions, in the prospects of analyzing the rate of plaque progression towards a higher degree of vulnerability. At the end of the 3-year period, patients will be assessed about the occurrence of major adverse cardiovascular events and the rate or revascularization for non-culprit lesions.
Study objectives:
Primary: to investigate the association between systemic, pancoronary and local vulnerability features of coronary plaques and the risk for major adverse cardiac events - MACE (all-cause mortality, cardiovascular death, myocardial infarction, repeated revascularization, repeated hospitalizations for cardiovascular related incidents, cerebrovascular events) during a 3-year follow-up.
Secondary: to assess the rate of progression for the non-culprit lesions towards a higher degree of vulnerability, as evaluated via coronary CT angiography at 1 year after enrollment, in relation to systemic, pancoronary and local vulnerability features at baseline.
To identify the type of vulnerability (systemic, pancoronary or local) with the highest impact on plaque progression and future MACE
Study Timeline:
Baseline (day 0)
- Obtain and document consent from participant on study consent form.
- Verify inclusion/exclusion criteria.
- Obtain demographic information, medical history, medication history, alcohol and tobacco use history.
- Record results of physical examinations and 12-lead ECG.
- Collect blood specimens.
- Imaging procedures: transthoracic 2-D echocardiography, 128-multisclice CT angiography, cardiac perfusion CT, IVUS, OCT
Visit 1 (month 1)
- Record results of physical examinations, 12-lead ECG and medical history.
- Imaging procedures: transthoracic 2-D echocardiography
Visit 2 (month 3)
- Telephone follow-up
Visit 3 (month 6)
- Record results of physical examinations, 12-lead ECG and medical history.
- Imaging procedures: transthoracic 2-D echocardiography
Visit 4 (month 12)
- Record results of physical examinations, 12-lead ECG and medical history.
- Imaging procedures: transthoracic 2-D echocardiography, 128-multislice CT coronary angiography for evaluation of non-culprit lesion
- End-point evaluation
Visit 5 (month 15)
- Telephone follow-up
Visit 6 (month 18)
- Telephone follow-up
Visit 7 (month 24)
- Record results of physical examinations, 12-lead ECG and medical history.
- Imaging procedures: transthoracic 2-D echocardiography.
- End-point evaluation
Visit 8 (month 30)
- Telephone follow-up
Final study visit (month 36)
- Record results of physical examinations, 12-lead ECG and medical history.
- Imaging procedures: transthoracic 2-D echocardiography
- End-point evaluation.
Study procedures:
- Clinical examination, medical history
- 12-lead ECG
- 2D transthoracic echocardiography with measurement of: cardiac diameters, volumes, valvular function and regurgitation, pressure gradients, pericardial fat thickness, pericardial effusion, left ventricular global and regional function and ejection fraction.
- 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity (degree of stenosis, lesion length, lumen area and diameter, minimum and maximum plaque thickness); morphological plaque characteristics (plaque related volumes, plaque burden, vascular indexes - remodeling and eccentricity index); plaque components evaluated via volumetric and planimetric units (necrotic core, fibrofatty tissue, fibrotic tissue, dense calcium); markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).
- Shear stress evaluation of CT acquired images and computational fluid dynamics
- Intracoronary imaging techniques: IVUS and OCT with evaluation of plaque characteristics.
- Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
Data collection: In a dedicated database that includes all patient information, demographics, medical history, medication, therapeutic procedures, information derived from imaging techniques (echocardiography, CT angiography, CT imaging post-processing and shear stress evaluation).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| VP-SG 01 | – | Diagnostic Test: Cardiac imaging tests, Diagnostic Test: Venous blood sample collectionStudy subjects that present MACE at the 36 months follow-up |
| VP-SG 02 | – | Diagnostic Test: Cardiac imaging tests, Diagnostic Test: Venous blood sample collectionStudy subjects that do not present MACE at the 36 months follow-up |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 100 patients with present ST and non-ST segment elevation myocardial infarction at 30 days prior to study enrollment, who underwent emergency revascularization of the culprit lesion.
Key inclusion criteria (2 listed)
- Patients aged over 18 years old that have signed the written informed consent;
- Patients with ST and non-ST segment elevation myocardial infarction (as stated in the Third Universal Definition of Myocardial Infarction) at 30 days prior to randomization;
Key exclusion criteria (8 listed)
- unwillingness or incapacity to provide informed consent (and if consent of legal guardian or family is not available);
- acute myocardial infarction at the moment of randomization (as these patients are referred to the hospital for emergency invasive coronary angiography and revascularization)
- conditions that present an estimated life expectancy of under 5 years;
- acute renal failure or terminal stage chronic kidney disease;
- pregnancy or lactation and women of reproductive age who are not using any contraceptive method;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cardiac imaging tests* 2D transthoracic echocardiography * 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling). * Shear stress evaluation via computational fluid dynamics. * Intracoronary imaging techniques: IVUS and OCT. | Diagnostic test | VP-SG 01, VP-SG 02 |
| Venous blood sample collectionVenous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP | Diagnostic test | VP-SG 01, VP-SG 02 |
Primary outcome
MACE rate - Major adverse cardiovascular events
Time frame: 36 months
Acute coronary syndromes (unstable angina, ST and non-ST elevation myocardial infarction), emergency revascularization of non-culprit lesions, repeated hospitalizations for cardiovascular reasons, acute cerebrovascular event.
2 secondary outcomes
Severity progression of non-culprit coronary lesions
Time frame: 12 months
Progression rate of CT markers for coronary plaque vulnerability
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Aug 2022.
- Individual participant dataSharing planned: Yes. All IPD that underlie results in a publication will be available for interested parties.
Related trials for Coronary Stenosis
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Not yet recruitingPhase 4
Application of TAVI at Experienced Interventional Cardiac Centers Without On-site Cardiac Surgery (ATLAS Study)
Aortic Stenosis, Severe Aortic Stenosis
Not yet recruiting
Exercise and Diet Supplements for Older Patients Undergoing TAVI: the IRON-TAVI Trial
Aortic Stenosis Disease, Aortic Stenosis Symptomatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Theodora Benedek, Professor study director
Cardio Med Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Stenosis and Acute Coronary Syndrome, run by Cardio Med Medical Center at 1 site in Romania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MACE rate - Major adverse cardiovascular events (time frame: 36 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2022.